Deutenzalutamide-d3

• CAT Number: S000413
• CAS Number: 1443331-82-5
• Molecular Formula: C21H13D3F4N4O2S
• Molecular Weight: 467.45
• Purity: ≥95%
• IUPAC Name: 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-(trideuteriomethyl)benzamide
• InChI: InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)/i3D3
• InChIKey: WXCXUHSOUPDCQV-HPRDVNIFSA-N
• SMILES: CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C

Deutenzalutamide-d3（Cat No.:S000413） is a deuterated form of enzalutamide, where three hydrogen atoms are replaced with deuterium. This modification aims to improve the drug’s metabolic stability and extend its half-life, making it valuable for pharmacokinetic research. Enzalutamide is an antiandrogen medication used primarily in the treatment of prostate cancer. It works by blocking androgens from binding to the androgen receptor, thereby inhibiting the growth of cancer cells reliant on these hormones. The deuterated form, Deutenzalutamide-d3, allows for more detailed studies on how the drug is metabolized in the body and its subsequent efficacy and safety.